Skip to main content
    A

    Aurinia Pharmaceuticals Inc (AUPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.40
    -0.08 (-0.52%)

    Market Cap: $2.11B

    Last updated: Nov 17, 2026 at 4:24 PM ET

    Aurinia Pharmaceuticals Inc (AUPH) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Aurinia Pharmaceuticals (AUPH) has a market cap of $2.11B and an enterprise value of $2.06B. It kept 97.68% of revenue as net income over the last 12 months. Revenue grew 21.04% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 2.19% below the market cap, as cash exceeds debt.

    Market Cap$2.11B
    Enterprise Value$2.06B
    Latest price (Nov 17, 2026)$15.40

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateOct 30, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.58% in the quarter ended Sep 30, 2026 and shrank 3.42% a year over 2 years.

    Shares Outstanding133.43M
    Shares Change (YoY)+1.23%
    Shares Change (QoQ)+2.58%
    Share Count Growth (2Y CAGR)-3.42%

    Valuation Ratios

    Sales and book value multiples are 6.4x and 3.1x.

    P/E Ratio15.1x
    Forward P/E15.5x
    P/S Ratio6.4x
    Forward P/S6.4x
    P/B Ratio3.1x
    P/TBV Ratio3.1x
    P/OCF Ratio11.9x
    PEG Ratio0.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 12.0x EBITDA.

    EV / Earnings6.6x
    EV / Sales6.4x
    EV / EBITDA12.0x

    Price Statistics

    The stock is up 0.33% over 52 weeks and trades 6.44% below its 50-day average.

    Beta (1Y)0.67
    52-Week Change+0.33%
    1-Month Change-6.61%
    3-Month Change-4.76%
    6-Month Change-0.96%
    5-Year Change-49.67%
    10-Year Change+449.50%
    Total Return (1Y)+0.33%
    Total Return (3Y CAGR)+21.43%
    Total Return (5Y CAGR)-12.29%
    Return vs SPY (1Y)-12.20%
    Max Drawdown (1Y)-21.75%
    Max Drawdown (3Y)-49.32%
    Sharpe Ratio (1Y)-0.02
    Correlation with SPY (1Y)0.26
    50-Day Average$16.46
    200-Day Average$15.74
    52-Week Range$13.52 to $19.25
    RSI (14 Days)36.7
    Average Volume (20 Days)934.03K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.12x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.12x
    Quick Ratio5.67x
    Debt / Equity0.00x
    Interest Coverage40.36x

    Returns and Efficiency

    Return on equity is 47.80% over the last 12 months, against a 5-year average of -6.83%.

    Return on Equity (ROE)47.80%
    Return on Assets (ROA)38.06%
    ROE (5Y Average)-6.83%
    ROA (5Y Average)-6.25%
    ROIC (5Y Average)18.05%
    Asset Turnover0.48x
    Inventory Turnover0.68x
    Receivables Turnover7.27x
    Cash Conversion Cycle559 days

    Scores

    AUPH has an Altman Z-Score of 8.13, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score8.13
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $321.74M over the last 12 months.

    Revenue$321.74M
    Revenue Growth (YoY)+21.04%
    Gross Profit$291.57M
    Operating Income$156.37M
    Pretax Income$167.12M
    Net Income$314.27M
    EBITDA$167.24M
    Reported EPS (TTM)$1.02

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.63% of the $825.70M in total assets.

    Cash and Equivalents$46.15M
    Total Debt$0
    Net Cash$46.15M
    Net Cash Per Share$0.35
    Working Capital$491.88M
    Shareholder Equity$657.52M
    Book Value Per Share$4.93
    Tangible Book Value$654.35M
    Tangible Book Per Share$4.90
    Total Assets$825.70M
    Total Liabilities$168.19M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$177.16M
    FCF Per Share$1.33
    Depreciation and Amortization$27.83M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 48.60%, against a 5-year average of -99.33%.

    Gross Margin90.62%
    Operating Margin48.60%
    Pretax Margin51.94%
    Net Margin97.68%
    EBITDA Margin51.98%
    Gross Margin (5Y Average)92.35%
    Operating Margin (5Y Average)-99.33%
    Net Margin (5Y Average)-83.61%

    Growth

    Revenue grew 28.30% a year over 3 years.

    Revenue Growth (3Y CAGR)+28.30%
    Revenue Growth (5Y CAGR)+41.38%
    Book Value Per Share Growth (2Y CAGR)+26.29%
    Tangible Book Per Share Growth (2Y CAGR)+26.72%

    Revenue and profit by year

    Dividends and Yields

    AUPH does not pay a dividend.

    Earnings Yield6.62%
    Buyback Yield3.63%
    Shareholder Yield3.63%

    Peer Position

    Against 9 similar companies, AUPH has the 6th highest P/S.

    P/S Ratio6.4x vs 6.8x median
    Revenue Growth (Trailing 4 Quarters, YoY)+21.04% vs +21.92% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 16.73% and EPS growth at 19.67% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+16.73%
    EPS Growth Forecast (2Y CAGR)+19.67%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AUPH

    What is AUPH's market cap?

    Aurinia Pharmaceuticals has a market cap of $2.11B. Its enterprise value, which adds debt and subtracts cash, is $2.06B.

    What is AUPH's P/E ratio?

    Aurinia Pharmaceuticals has a trailing P/E ratio of 15.1x and a forward P/E of 15.5x.

    How many shares of AUPH are outstanding?

    Aurinia Pharmaceuticals has 133.43M shares outstanding. The count is up 1.23% from a year earlier.

    Does AUPH pay a dividend?

    No. Aurinia Pharmaceuticals does not pay a dividend.

    How much debt does AUPH have?

    Aurinia Pharmaceuticals has $0 of total debt and $46.15M of cash and equivalents, a net cash position of $46.15M.